The G-Can (GBA1 Canada) Consortium is a national initiative focused on advancing research and clinical translation for Parkinson’s disease and related disorders linked to GBA1 variants. G-Can brings together scientific, clinical, and patient-focused partners to build an integrated platform that supports discovery, data harmonization, and open-science collaboration across Canada.
The consortium’s goals include improving understanding of the genetic and molecular mechanisms of GBA1-associated disease, establishing standardized pipelines for variant interpretation and functional testing, and enabling the development and evaluation of emerging therapeutics that target GCase deficiency and related lysosomal pathways. G-Can also promotes knowledge sharing, national–international partnerships, and training opportunities to accelerate meaningful progress for patients affected by GBA1-related conditions.